Latest News
Summit Therapeutics Inc.
- AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Why is Summit Therapeutics stock up 4.1% today?
- AstraZeneca Makes $2B Equity Investment in Summit Therapeutics
- AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
- AZ takes stake in Summit Therapeutics in $2bn deal
- Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal
- Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
- AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
- AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer
- AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
- Summit Therapeutics rises after AstraZeneca commits $2B investment
Headlines from the last 30 days, linking to the original publishers. See all market news →